Asset profile

Serplulimab

Monoclonal antibody

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2031-01.

How the evidence outlook works ↗

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (3)
October 2026 (2)
Phase 2Early Lung CancerNot yet recruiting
Est. primary completion 2026-10 · NCT07064876 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-10-30 · NCT06848699 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (1)
Phase 2Triple Negative Breast CancerRecruiting
Est. primary completion 2026-12 · NCT07283692 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (3)
May 2027 (1)
Phase 2Breast Cancer (Triple Negative Breast Cancer (TNBC))Not yet recruiting
Est. primary completion 2027-05-15 · NCT07487519 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-18 · NCT07253142 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT07398937 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (3)
February 2028 (2)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-02 · NCT07418866 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast CancerNot yet recruiting
Est. primary completion 2028-02-01 · NCT07466303 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (1)
Phase 2HR+/HER2- Breast CancerRecruiting
Est. primary completion 2028-03-31 · NCT06860529 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (1)
January 2031 (1)
Phase 2/3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-01 · NCT07318883 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.